{"DataElement":{"publicId":"5582959","version":"1","preferredName":"Prior Agent Intervention or Procedure Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to assessments of prior substances and activities that produce an effect, or intended to alter the course of disease as outlined in the protocol.","longName":"PR_AGTIVN_ASMT_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"5582956","version":"1","preferredName":"Prior Agent Intervention or Procedure Assessment Clinical Trial Eligibility Criteria","preferredDefinition":"Earlier in time or order._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects._The final result of a determination of the value, significance, or extent of._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"5582953v1.0:5582954v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"5582953","version":"1","preferredName":"Prior Agent Intervention or Procedure","preferredDefinition":"Earlier in time or order.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.:An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.","longName":"C25629:C1708:C25218","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Intervention or Procedure","conceptCode":"C25218","definition":"An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4288623F-37D0-1850-E053-F662850A470C","latestVersionIndicator":"Yes","beginDate":"2016-11-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-30","modifiedBy":"ONEDATA","dateModified":"2016-11-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5582954","version":"1","preferredName":"Assessment Clinical Trial Eligibility Criteria","preferredDefinition":"The final result of a determination of the value, significance, or extent of.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"C25217:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Assessment","conceptCode":"C25217","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4288623F-37E1-1850-E053-F662850A470C","latestVersionIndicator":"Yes","beginDate":"2016-11-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-30","modifiedBy":"ONEDATA","dateModified":"2016-11-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4288623F-37F2-1850-E053-F662850A470C","latestVersionIndicator":"Yes","beginDate":"2016-11-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-30","modifiedBy":"SOKKERL","dateModified":"2017-02-23","changeDescription":"11/30/16 tt, 9984.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"10000494","version":"1","longName":"Prior Treatments","context":"Theradex"}]},{"publicId":"5999742","version":"1","longName":"CRF CDEs","context":"CITN","ClassificationSchemeItems":[{"publicId":"5999747","version":"1","longName":"Eligibility CDEs","context":"CITN"}]}],"AlternateNames":[{"name":"CITN","type":"USED_BY","context":"CITN"},{"name":"Theradex","type":"USED_BY","context":"Theradex"}],"ReferenceDocuments":[{"name":"If patient has received prior","type":"Preferred Question Text","description":"If patient has received prior prednisone or requires the concurrent use of prednisone was dose up to 5mg bid or equivalent for symptom control. And the treatment was initiated prior to commencing the trial medication with evidence of progression on the dose of steroids?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"If patient has been treated with blinatumomab in the past, do they have persistent CD19 expression on leukemia cells and did not experience unacceptable toxicities with prior blinatumomab administration?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Has patient had any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity (e.g. doxorubicin), biologic therapy, or immunotherapy within 21 days prior to enrollment and/or daily or weekly chemotherapy (e.g. sunitinib, sorafenib and pazopanib) without the potential for delayed toxicity within 14 days prior to enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"If patient has colorectal cancer (Cohort 2) did patient progress on first line chemotherapy?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"If patient has previously tolerated IFN-gamma, have they been off IFN-gamma for at least 3 weeks prior to initiation of therapy on this trial?","url":null,"context":"Theradex"},{"name":"CITN-1","type":"Alternate Question Text","description":"Patients with prior treatment with IFN-gamma will be eligible if they previously tolerated IFN-gamma. However, patient must be off IFN-gamma for at least 3 weeks prior to initiation of therapy on this trial.","url":null,"context":"CITN"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"If patient has received daily or weekly chemotherapy without the potential for delayed toxicity, has a washout period of 14 days elapsed and questions related to this have been discussed with study Principal Investigator?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Has patient had major surgery and biologic/antibody therapies (including immunotherapies) within 4 weeks of romidepsin administration?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Has patient received strong (e.g., phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate (e.g., bosentan, efavirenz, modafinil) CYP3A inducers within 3 weeks (5 weeks for enzalutamide or phenobarbital) prior to starting olaparib?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"If patient has evidence of refractory AML, does patient have less than or equal to 2 prior induction regimens (example: patients who receive 7+3 followed by 5+2 would count as one induction regimen) or a minimum of two cycles of any hypomethylating agent-based therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"If patient has previously received lenalidomide, erythropoiesis-stimulating agents (ESAs), and growth factors is allowed was it used to treat prior MDS?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Has patient received prior treatment with nitrosoureas or mitomycin C?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Have at least 7 days elapsed since last dose of anti-cancer agents not known to be myelosuppressive to initiation of protocol therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"If patient has received prior immunomodulatory therapy and checkpoint inhibitor therapy, was the therapy previously tolerated without severe toxicities?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Have at least 7 days elapsed since the completion of therapy with a biologic agent, tyrosine kinase inhibitor, targeted agent, or metronomic non-myelosuppressive regimen prior to leukapheresis?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"If patient has received prior paclitaxel in the adjuvant or neoadjuvant setting, was it completed more than 6 months prior to Radium-223 dichloride start?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"If patient was prescribed prednisone 10 mg PO daily or less (or equivalent), has patient been on a stable dose for at least 4 weeks prior to enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"For patients undergoing leukapheresis: Prior to leukapheresis have at least 7 days elapsed since the completion of therapy with a biologic agent, tyrosine kinase inhibitor, targeted agent, or metronomic non-myelosuppressive regimen?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"If patient is to be enrolled in the Phase 2 or non-thoracic, non-BRD4 exploratory cohort, has patient previously received treatment with a BETi, including but not limited to previous ZEN003694 therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Has patient received chemotherapy, targeted therapies, immunotherapy, or treatment with an investigational anticancer agent within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"Has patient received anti-plasma cell therapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Has patient received prior treatment with ZEN003694 or has been treated with an HDAC inhibitor or investigational BET inhibitor?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"Has patient received prior treatment with ZEN003694 or has been treated with an HDAC inhibitor or investigational BET inhibitor?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Was last treatment with any chemotherapy greater than or equal to 3 weeks or other investigational therapy including hormonal, biological or targeted agents greater than or equal to 4 weeks or at least 5 half-lives from hormonal, biological or targeted agents, whichever is shorter at the time of treatment initiation?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"Has patient received prior BET inhibitor therapy within two weeks prior to entering the study?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"If patient is enrolled in the topotecan arm, was patient previously treated with topotecan?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"If patient has only received previous durvalumab (anti-PD-1), was the treatment as part of first line in combination with gemcitabine and cisplatin (TOPAZ-1 regimen [NCT03875235])?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"If patient has only received previous durvalumab (anti-PD-L1), was the treatment as part of first line in combination with gemcitabine and cisplatin (TOPAZ-1 regimen [NCT03875235])?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"If patient has received erythropoietin stimulating agents (ESA) and thrombopoietic agents previously, was it discontinued 4 weeks prior to study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"If patient has MSI or dMMR endometrial cancer, has patient received prior PD-1 or PD-L1 directed IO therapy or be considered medically ineligible to receive such therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"Has patient received prior treatment with a DNA-PK inhibitor?","url":null,"context":"Theradex"},{"name":"NRG CRF Text 1","type":"Alternate Question Text","description":"Has the patient received treatment with a PD-1 inhibitor (except if given as adjuvant or neoadjuvant therapy for melanoma), PD-L1 inhibitor, anti-PD-L2 inhibitor, LAG-3 inhibitor, CTLA-4 inhibitor (except if given as adjuvant or neoadjuvant therapy for non-recurrent and non-metastatic NPC), or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.","url":null,"context":"NRG"},{"name":"NRG CRF Text 2","type":"Alternate Question Text","description":"Has the patient received treatment with a PD-1 inhibitor (except if given as adjuvant or neoadjuvant therapy for NPC), PD-L1 inhibitor, anti-PD-L2 inhibitor, LAG-3 inhibitor, CTLA-4 inhibitor (except if given as adjuvant or neoadjuvant therapy for non-recurrent and non-metastatic NPC), or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.","url":null,"context":"NRG"},{"name":"NRG CRF Text 3","type":"Alternate Question Text","description":"Did the patient receive inhibitors/inducers of P-gp within 14 days prior to registration?","url":null,"context":"NRG"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"If patient is registered to the Phase 2 portion of study, has patient received prior anti-CTLA-4, anti-PD-1, anti-PD-L1 or other immune checkpoint inhibitor therapeutic antibodies or pathway-targeting agents with the exception of; Patients who have only received previous durvalumab (anti-PD-L1) in combination with gemcitabine +/- cisplatin as part of first line therapy (TOPAZ-1 regimen) or Patients who have only received previous pembrolizumab (anti-PD-1) in combination with gemcitabine +/- cisplatin as part of first line therapy (KEYNOTE-966 regimen)?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"42887499-E845-21F7-E053-F662850A7970","latestVersionIndicator":"Yes","beginDate":"2016-11-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-30","modifiedBy":"SOKKERL","dateModified":"2023-07-18","changeDescription":"11/30/16 tt, 9984.","administrativeNotes":"8/4/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"}}